Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
167.54
-0.52 (-0.31%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Krystal Biotech Revenue
In the year 2024, Krystal Biotech had annual revenue of $290.52M with 473.02% growth. Krystal Biotech had revenue of $91.14M in the quarter ending December 31, 2024, with 116.26% growth.
Revenue (ttm)
$290.52M
Revenue Growth
+473.02%
P/S Ratio
16.70
Revenue / Employee
$1,056,418
Employees
275
Market Cap
4.90B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
KRYS News
- 20 hours ago - Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 4 days ago - Krystal Biotech to Present at Upcoming Scientific Conferences - GlobeNewsWire
- 21 days ago - Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer - GlobeNewsWire
- 5 weeks ago - Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK - Seeking Alpha
- 2 months ago - Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 2 months ago - Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus - Seeking Alpha
- 2 months ago - Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewsWire